| Literature DB >> 24139583 |
Jian Jeffrey Chen1, Wenyuan Qian, Kaustav Biswas, Chester Yuan, Albert Amegadzie, Qingyian Liu, Thomas Nixey, Joe Zhu, Mqhele Ncube, Robert M Rzasa, Frank Chavez, Ning Chen, Frenel DeMorin, Shannon Rumfelt, Christopher M Tegley, Jennifer R Allen, Stephen Hitchcock, Randy Hungate, Michael D Bartberger, Leeanne Zalameda, Yichin Liu, John D McCarter, Jianhua Zhang, Li Zhu, Safura Babu-Khan, Yi Luo, Jodi Bradley, Paul H Wen, Darren L Reid, Frank Koegler, Charles Dean, Dean Hickman, Tiffany L Correll, Toni Williamson, Stephen Wood.
Abstract
γ-Secretase modulators (GSMs) are potentially disease-modifying treatments for Alzheimer's disease. They selectively lower pathogenic Aβ42 levels by shifting the enzyme cleavage sites without inhibiting γ-secretase activity, possibly avoiding known adverse effects observed with complete inhibition of the enzyme complex. A cell-based HTS effort identified the sulfonamide 1 as a GSM lead. Lead optimization studies identified compound 25 with improved cell potency, PKDM properties, and it lowered Aβ42 levels in the cerebrospinal fluid (CSF) of Sprague-Dawley rats following oral administration. Further optimization of 25 to improve cellular potency is described.Entities:
Keywords: Alzheimer’s disease (AD); Amide as sulfonamide replacement; Amyloid β-protein (Aβ); Methylpyridine; γ-Secretase inhibitor (GSI); γ-Secretase modulator (GSM)
Mesh：
Substances：
Year: 2013 PMID： 24139583 DOI： 10.1016/j.bmcl.2013.09.041
Source DB: PubMed Journal: Bioorg Med Chem Lett ISSN： 0960-894X Impact factor: 2.823